<?xml version='1.0' encoding='utf-8'?>
<document id="19944137"><sentence text="MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting."><entity charOffset="37-49" id="DDI-PubMed.19944137.s1.e0" text="indomethacin" /><entity charOffset="60-73" id="DDI-PubMed.19944137.s1.e1" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s1.e0" e2="DDI-PubMed.19944137.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s1.e0" e2="DDI-PubMed.19944137.s1.e1" /></sentence><sentence text="We have recently shown that efflux transport, mediated by multidrug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP), is responsible for sulfasalazine low-permeability in the small intestine, thereby enabling its colonic targeting and therapeutic action"><entity charOffset="171-184" id="DDI-PubMed.19944137.s2.e0" text="sulfasalazine" /></sentence><sentence text=" The purpose of the present study was to evaluate the potential pharmacokinetic interaction between indomethacin and sulfasalazine, in the mechanism of efflux transporter competition"><entity charOffset="100-112" id="DDI-PubMed.19944137.s3.e0" text="indomethacin" /><entity charOffset="117-130" id="DDI-PubMed.19944137.s3.e1" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s3.e0" e2="DDI-PubMed.19944137.s3.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s3.e0" e2="DDI-PubMed.19944137.s3.e1" /></sentence><sentence text=" The concentration-dependent effects of indomethacin on sulfasalazine intestinal epithelial transport were investigated across Caco-2 cell monolayers, in both apical to basolateral (AP-BL) and BL-AP directions"><entity charOffset="40-52" id="DDI-PubMed.19944137.s4.e0" text="indomethacin" /><entity charOffset="56-69" id="DDI-PubMed.19944137.s4.e1" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s4.e0" e2="DDI-PubMed.19944137.s4.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s4.e0" e2="DDI-PubMed.19944137.s4.e1" /></sentence><sentence text=" The interaction was then investigated in the in situ single-pass rat jejunal perfusion model" /><sentence text=" Sulfasalazine displayed 30-fold higher BL-AP than AP-BL Caco-2 permeability, indicative of net mucosal secretion"><entity charOffset="1-14" id="DDI-PubMed.19944137.s6.e0" text="Sulfasalazine" /></sentence><sentence text=" Indomethacin significantly increased AP-BL and decreased BL-AP sulfasalazine Caco-2 transport, in a concentration-dependent manner, with IC(50) values of 75 and 196 microM respectively"><entity charOffset="1-13" id="DDI-PubMed.19944137.s7.e0" text="Indomethacin" /><entity charOffset="64-77" id="DDI-PubMed.19944137.s7.e1" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s7.e0" e2="DDI-PubMed.19944137.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s7.e0" e2="DDI-PubMed.19944137.s7.e1" /></sentence><sentence text=" In the rat model, higher sulfasalazine concentrations resulted in higher intestinal permeability, consistent with saturation of efflux transporter"><entity charOffset="26-39" id="DDI-PubMed.19944137.s8.e0" text="sulfasalazine" /></sentence><sentence text=" Without indomethacin, sulfasalazine demonstrated low rat jejunal permeability (vs"><entity charOffset="9-21" id="DDI-PubMed.19944137.s9.e0" text="indomethacin" /><entity charOffset="23-36" id="DDI-PubMed.19944137.s9.e1" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s9.e0" e2="DDI-PubMed.19944137.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s9.e0" e2="DDI-PubMed.19944137.s9.e1" /></sentence><sentence text=" metoprolol)"><entity charOffset="1-11" id="DDI-PubMed.19944137.s10.e0" text="metoprolol" /></sentence><sentence text=" Indomethacin significantly increased sulfasalazine P(eff), effectively shifting it from BCS (biopharmaceutics classification system) Class IV to II"><entity charOffset="1-13" id="DDI-PubMed.19944137.s11.e0" text="Indomethacin" /></sentence><sentence text=" In conclusion, the data indicate that concomitant intake of indomethacin and sulfasalazine may lead to increased absorption of sulfasalazine in the small intestine, thereby reducing its colonic concentration and potentially altering its therapeutic effect"><entity charOffset="61-73" id="DDI-PubMed.19944137.s12.e0" text="indomethacin" /><entity charOffset="78-91" id="DDI-PubMed.19944137.s12.e1" text="sulfasalazine" /><entity charOffset="128-141" id="DDI-PubMed.19944137.s12.e2" text="sulfasalazine" /><pair ddi="false" e1="DDI-PubMed.19944137.s12.e0" e2="DDI-PubMed.19944137.s12.e0" /><pair ddi="false" e1="DDI-PubMed.19944137.s12.e0" e2="DDI-PubMed.19944137.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19944137.s12.e0" e2="DDI-PubMed.19944137.s12.e2" /><pair ddi="false" e1="DDI-PubMed.19944137.s12.e1" e2="DDI-PubMed.19944137.s12.e1" /><pair ddi="false" e1="DDI-PubMed.19944137.s12.e1" e2="DDI-PubMed.19944137.s12.e2" /></sentence><sentence text="" /></document>